This webinar is intended to highlight and discuss: The Process of Drug Discovery to Clinic.

This symposium is intended to provide perspectives on the impact that the ICH M12 guideline will have on the in vitro DDI studies required for drug development.

This webinar will highlight how primary human cells play a key role in the performance of Liver Tissue Chips, which are at the forefront of drug development technology. The Liver Tissue Chip, which utilizes primary cells such as human hepatocytes and non-parenchymal cells, represents a significant advancement in the field, offering a promising tool for predicting pharmacokinetic profiles, toxicodynamic assessment and drug safety evaluation in alignment with human physiology.

This symposium is intended to provide insights on best practices to address the challenges associated with conducting drug transporter studies with compounds that are unstable, sticky or unstable.

In this webinar, we are going to walk through the main elements of an in vitro DDI investigation study with a focus on changes in this new guidance compared to those previously published by FDA, EMA, and PMDA.

This presentation will demonstrate the difference between lipidomic profile of hepatocytes from patients with nonalcoholic steatohepatitis (NASH) and hepatocytes cultured in fatty acid-enriched media, a commonly used in vitro model to study NASH.

This webinar, sponsored by Inotiv, will focus on proximal tubule functions and the important role of drug transporters with mediating renal clearance and toxicity.